SOURCE: Equity News Circuit

Equity News Circuit

April 16, 2013 08:20 ET

Free Research Reports on BBG, GENE, JKS and SVA Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - Apr 16, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Bill Barrett Corporation (NYSE: BBG) shares declined 9.70 percent on more than double the average daily volume Monday to close at $18.53 a share. Energy stocks fell sharply Monday as oil futures declined 3 percent to close at its lowest level of the year after China reported gross domestic product increase just 7.7 percent in the first quarter, down from growth of 7.9 percent in the previous quarter.

Find out more about Bill Barrett including full access to the free equity report at: www.ParagonReport.com/BBG

Genetic Technologies Limited (NASDAQ: GENE) shares surged 22.77 percent on volume of 1.80 million shares traded Monday to close at $2.75 a share. The company's U.S. subsidiary, Phenogen Sciences, Inc., reported results from a recent study showed that BREVAGen "more accurately identifies a woman's chances of getting breast cancer than the Breast Cancer Risk Assessment Tool (BCRAT) alone".

Find out more about Genetic Technologies including full access to the free equity report at: www.ParagonReport.com/GENE

JinkoSolar Holding Co., Ltd. (NYSE: JKS) shares declined 15.59 percent on volume of 627,353 shares traded Monday to close at $4.82 a share. Zacks analysts have recently downgraded the company's rating to "underperform" from "neutral" and currently have a $5.40 price target on the stock.

Find out more about JinkoSolar including full access to the free equity report at: www.ParagonReport.com/JKS

Sinovac Biotech Ltd. (NASDAQ: SVA) shares spiked 6.75 percent on more than double the average daily volume Monday to close at $4.11 a share. The Company has developed a portfolio of products, consisting of vaccines against the hepatitis A, hepatitis B and influenza viruses. Sinovac shares have recently been boosted by the Avian Flu (H7N9) outbreak in China.

Find out more about Sinovac Biotech including full access to the free equity report at: www.ParagonReport.com/SVA

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information